University Hospital, Strasbourg, France
chru-strasbourg.frTotal trials
957
Active
249
Phase 3
34
Total enrollment
1,066,836
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 44 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Biological collection | — | — | — | — | — | 1 | |
| Diclofenac gel | — | — | — | — | — | 1 | |
| Aromatherapy gel | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Hydrocortisone Hemisuccinate: 200 mg per day. | — | — | — | — | — | 1 | |
| Prothrombin time | — | — | — | — | — | 1 | |
| Rituximab 200mg/6months | — | — | — | — | — | 1 | |
| Rituximab 1g/6months | — | — | — | — | — | 1 | |
| Methotrexate + targeted therapy administration | — | — | — | — | — | 1 | |
| methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration | — | — | — | — | — | 1 | |
| Isotretinoin | — | — | — | — | — | 1 | |
| Control group | — | — | — | — | — | 1 | |
| Dornase Alfa Inhalant Solution [Pulmozyme] | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| pediatric, prolonged released melatonin | — | — | — | — | — | 1 | |
| Dapaglifozin | — | — | — | — | — | 1 | |
| Methylphenidate immediate release 25mg | — | — | — | — | — | 1 | |
| Spironolactone | — | — | — | — | — | 1 | |
| treatment withdrawal | — | — | — | — | — | 1 | |
| Usual DMT continuation | — | — | — | — | — | 1 | |
| no NSAID | — | — | — | — | — | 1 | |
| protocol for administering NSAIDs already used in routine care | — | — | — | — | — | 1 | |
| Trametinib | — | — | — | — | — | 1 | |
| Vinblastine | — | — | — | — | — | 1 | |
| • Sivelestat intravenous | — | — | — | — | — | 1 | |
| NaCl intravenous | — | — | — | — | — | 1 | |
| - Melatonin - Active light ttherapy | — | — | — | — | — | 1 | |
| - Placebo drug - Placebo light therapy | — | — | — | — | — | 1 | |
| Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for | — | — | — | — | — | 1 | |
| Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup | — | — | — | — | — | 1 | |
| Biological samples will be done to evaluate the endothelial and leukocyte senescence. | — | — | — | — | — | 1 | |
| genetic analysis | — | — | — | — | — | 1 | |
| blood draw | — | — | — | — | — | 1 | |
| Cladribine | — | — | — | — | — | 1 | |
| Prothrombin | — | — | — | — | — | 1 | |
| Molecular monitoring by quantification of cell-free DNA | — | — | — | — | — | 1 | |
| Skin biopsy | — | — | — | — | — | 1 | |
| Chemotherapy drug | — | — | — | — | — | 1 | |
| An additional volume of blood will be drawn as part of routine follow-up care | — | — | — | — | — | 1 | |
| The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons | — | — | — | — | — | 1 |
4 more active programs hidden
Next readouts
- 2020-01
- 2024-12-14
- 2025-02
- 2025-05-27
- 2025-06
- 2025-08-01
- 2025-10-12
- 2025-12
- 2026-03
- 2026-04-01
Top conditions
- Schizophrenia18
- COVID-1916
- Covid-1912
- Multiple Sclerosis7
- Breast Cancer7
- Cystic Fibrosis6
- Rheumatoid Arthritis6
- Cancer6
Frequently asked questions about University Hospital, Strasbourg, France
- How many clinical trials does University Hospital, Strasbourg, France have on ClinicalTrials.gov?
- University Hospital, Strasbourg, France is listed as the lead sponsor on 957 clinical trials in ClinicalTrials.gov, 249 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Strasbourg, France's trials are in Phase 3?
- 34 of University Hospital, Strasbourg, France's trials are in Phase 3, spread across 44 active drug programs.
- What therapeutic areas does University Hospital, Strasbourg, France focus on?
- University Hospital, Strasbourg, France's most-studied conditions on ClinicalTrials.gov are Schizophrenia, COVID-19, Covid-19, Multiple Sclerosis, Breast Cancer.
- When are University Hospital, Strasbourg, France's next clinical trial readouts?
- University Hospital, Strasbourg, France has 10 upcoming primary-completion readouts tracked here; the soonest is “Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients”, expected around 2020-01.